Clearmind Completes Dosing for Phase I/II Trial of Alcohol Use Disorder Treatment
Event summary
- Clearmind Medicine completed dosing for all 24 participants in Cohorts 1 through 4 of Part A of its Phase I/II clinical trial for CMND-100, a treatment for Alcohol Use Disorder (AUD).
- The trial is being conducted under FDA oversight as a multicenter, randomized, double-blind, placebo-controlled study.
- Interim results from the first three cohorts show a strong safety profile for CMND-100.
- Trial sites include Yale School of Medicine, Johns Hopkins University School of Medicine, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center.
The big picture
Clearmind's completion of dosing for Part A of its Phase I/II trial marks a significant milestone in the development of non-hallucinogenic treatments for Alcohol Use Disorder. The rapid patient recruitment and efficient treatment timelines across leading clinical sites in the U.S. and Israel highlight the growing interest in psychedelic-derived therapeutics. The strong safety profile observed so far positions Clearmind favorably in the competitive landscape of neuroplastogen-derived treatments.
What we're watching
- Regulatory Progress
- How the FDA's oversight will impact the timeline and approval process for CMND-100.
- Safety Profile
- Whether the strong safety profile observed in the initial cohorts will be sustained in later stages of the trial.
- Clinical Execution
- The pace at which Clearmind can advance to Part B of the trial and potentially move into later-phase studies.
Related topics